Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

45.7%

16 terminated/withdrawn out of 35 trials

Success Rate

38.5%

-48.0% vs industry average

Late-Stage Pipeline

86%

30 trials in Phase 3/4

Results Transparency

20%

2 of 10 completed trials have results

Key Signals

2 with results13 withdrawn

Enrollment Performance

Analytics

Phase 3
27(77.1%)
Phase 4
3(8.6%)
Phase 1
2(5.7%)
Phase 2
2(5.7%)
N/A
1(2.9%)
35Total
Phase 3(27)
Phase 4(3)
Phase 1(2)
Phase 2(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (35)

Showing 20 of 35 trials
NCT07270432Phase 3Not Yet Recruiting

Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia

Role: lead

NCT04487860Phase 2Completed

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

Role: lead

NCT06577077Phase 3Not Yet Recruiting

Efficacy/ Safety of Product CM9241GRU in Patients With Perennial Allergic Rhinitis

Role: lead

NCT06355856Phase 4Not Yet Recruiting

Efficacy/ Safety of DNN.22.17.036 in Male Patients With Pattern Hair Loss

Role: lead

NCT02582177Phase 3Completed

Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis

Role: lead

NCT02798367Phase 2Unknown

Melatonin 3mg and 5mg Compared to Cognitive Behavioral Therapy for Insomnia (CBT-I) in the Treatment of Insomnia

Role: lead

NCT02985671Phase 3Unknown

To Evaluate the Superiority of Fixed Combination (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to Voltaren® (Diclofenac Sodium 50mg) in the Treatment of Acute Postural Low Back Pain.

Role: lead

NCT04327401Phase 3Terminated

COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III

Role: collaborator

NCT01420549Phase 3Completed

Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia

Role: lead

NCT02904304Phase 3Suspended

Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu

Role: lead

NCT03508167Phase 3Withdrawn

Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.

Role: lead

NCT02853578Phase 3Suspended

Busonid® (Budesonide 200 mcg and 400 mcg) to Treat Asthma Not Controlled or Partially Controlled

Role: lead

NCT02582996Phase 3Suspended

Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks

Role: lead

NCT02706015Phase 3Withdrawn

Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks

Role: lead

NCT03634514Phase 4Unknown

Non-inferiority Evaluation of Pain Intensity After Biomatrop (Somatropin) Application in Relation to Hormotrop (Somatropin), in Healthy Subjects

Role: lead

NCT02581397Phase 3Terminated

Transpulmin Suppository and Guaiacol Compared to Transpulmin Syrup in Pediatric Participants With Productive Cough

Role: lead

NCT01199497Phase 3Withdrawn

Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Diphenhydramine + Pseudoephedrine + Dropropizine in the Control of Cough and the Relief of Nasal Symptoms, Suffering From Non-productive Cough and Acute Rhinitis

Role: lead

NCT02716090Phase 3Withdrawn

Clinical Trial Phase III to Assess the Non-inferiority of Dalap Duo® Product Compared to Epiduo® in the Treatment of Acne Vulgaris

Role: lead

NCT02584010Not ApplicableWithdrawn

Efficacy Study of Two Silicon-based Products to Treat Scars

Role: lead

NCT01393145Phase 3Withdrawn

Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD

Role: lead